25 related articles for article (PubMed ID: 7686601)
1. Deciphering molecular mechanisms underlying chemoresistance in relapsed AML patients: towards precision medicine overcoming drug resistance.
Levin M; Stark M; Ofran Y; Assaraf YG
Cancer Cell Int; 2021 Jan; 21(1):53. PubMed ID: 33446189
[TBL] [Abstract][Full Text] [Related]
2. The Novel Phospholipid Mimetic KPC34 Is Highly Active Against Acute Myeloid Leukemia with Activated Protein Kinase C.
Alexander PM; Kucera GL; Pladna KM; Pardee TS
Transl Oncol; 2020 Jul; 13(7):100780. PubMed ID: 32428837
[TBL] [Abstract][Full Text] [Related]
3. Surmounting Cytarabine-resistance in acute myeloblastic leukemia cells and specimens with a synergistic combination of hydroxyurea and azidothymidine.
Levin M; Stark M; Berman B; Assaraf YG
Cell Death Dis; 2019 May; 10(6):390. PubMed ID: 31101804
[TBL] [Abstract][Full Text] [Related]
4. Mechanisms of resistance to decitabine in the myelodysplastic syndrome.
Qin T; Castoro R; El Ahdab S; Jelinek J; Wang X; Si J; Shu J; He R; Zhang N; Chung W; Kantarjian HM; Issa JP
PLoS One; 2011; 6(8):e23372. PubMed ID: 21858090
[TBL] [Abstract][Full Text] [Related]
5. The human equilibrative nucleoside transporter 1 mediates in vitro cytarabine sensitivity in childhood acute myeloid leukaemia.
Hubeek I; Stam RW; Peters GJ; Broekhuizen R; Meijerink JP; van Wering ER; Gibson BE; Creutzig U; Zwaan CM; Cloos J; Kuik DJ; Pieters R; Kaspers GJ
Br J Cancer; 2005 Dec; 93(12):1388-94. PubMed ID: 16333246
[TBL] [Abstract][Full Text] [Related]
6. Immunocytochemical detection of deoxycytidine kinase in haematological malignancies and solid tumours.
Hubeek I; Peters GJ; Broekhuizen AJ; Talianidis I; Sigmond J; Gibson BE; Creutzig U; Giaccone G; Kaspers GJ
J Clin Pathol; 2005 Jul; 58(7):695-9. PubMed ID: 15976334
[TBL] [Abstract][Full Text] [Related]
7. New targets for pyrimidine antimetabolites for the treatment of solid tumours. 2: Deoxycytidine kinase.
Ruiz van Haperen VW; Peters GJ
Pharm World Sci; 1994 Apr; 16(2):104-12. PubMed ID: 7980770
[TBL] [Abstract][Full Text] [Related]
8. Cellular pharmacology of N4-hexadecyl-1-beta-D-arabinofuranosylcytosine in the human leukemic cell lines K-562 and U-937.
Horber DH; Schott H; Schwendener RA
Cancer Chemother Pharmacol; 1995; 36(6):483-92. PubMed ID: 7554040
[TBL] [Abstract][Full Text] [Related]
9. Induction of deoxycytidine kinase by 5-azacytidine in an HL-60 cell line resistant to arabinosylcytosine.
Kong XB; Tong WP; Chou TC
Mol Pharmacol; 1991 Feb; 39(2):250-7. PubMed ID: 1705001
[TBL] [Abstract][Full Text] [Related]
10. Molecular, cellular and animal pharmacology of 5-aza-2'-deoxycytidine.
Momparler RL
Pharmacol Ther; 1985; 30(3):287-99. PubMed ID: 2433703
[No Abstract] [Full Text] [Related]
11. Role of deoxycytidine kinase in an in vitro model for AraC- and DAC-resistance: substrate-enzyme interactions with deoxycytidine, 1-beta-D-arabinofuranosylcytosine and 5-aza-2'-deoxycytidine.
Stegmann AP; Honders MW; Kester MG; Landegent JE; Willemze R
Leukemia; 1993 Jul; 7(7):1005-11. PubMed ID: 7686601
[TBL] [Abstract][Full Text] [Related]
12. In vitro-induced resistance to the deoxycytidine analogues cytarabine (AraC) and 5-aza-2'-deoxycytidine (DAC) in a rat model for acute myeloid leukemia is mediated by mutations in the deoxycytidine kinase (dck) gene.
Stegmann AP; Honders MW; Hagemeijer A; Hoebee B; Willemze R; Landegent JE
Ann Hematol; 1995 Jul; 71(1):41-7. PubMed ID: 7543292
[TBL] [Abstract][Full Text] [Related]
13. De novo induced mutations in the deoxycytidine kinase (dck) gene in rat leukemic clonal cell lines confer resistance to cytarabine (AraC) and 5-aza-2'-deoxycytidine (DAC).
Stegmann AP; Honders MW; Willemze R; Landegent JE
Leukemia; 1995 Jun; 9(6):1032-8. PubMed ID: 7541096
[TBL] [Abstract][Full Text] [Related]
14. Transfection of wild-type deoxycytidine kinase (dck) cDNA into an AraC- and DAC-resistant rat leukemic cell line of clonal origin fully restores drug sensitivity.
Stegmann AP; Honders WH; Willemze R; Ruiz van Haperen VW; Landegent JE
Blood; 1995 Mar; 85(5):1188-94. PubMed ID: 7532033
[TBL] [Abstract][Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]